Biomarker ID | 1732 |
PMID | 30286759 |
Year | 2018 |
Biomarker | SERPINA5; MFSD2A; ACSL6; MCF2; EMX2; HOXB8; CLDN2; AKR1B1; SPINK2; CYP19A1; |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Differentially Expressed [Log Fold Change: SERPINA5: (-6.78954); MFSD2A (− 5.97025); ACSL6: (− 4.99597); MCF2: (−5.26855); EMX2: (− 6.79059); HOXB8: (− 6.24965); CLDN2: (−7.91887); AKR1B1: (− 3.87736); SPINK2: (−7.41992); CYP19A1: (−5.40444;] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | High Risk Vs Low Risk PCa |
Type of Biomarker | Prognostic |
Cohort | A total of 551 samples were collected, comprising 499 primary prostate cancer samples and 52 normal solid tissue samples.Out of 499 patients, 247 were classified as high risk group, and 248 in low risk group |
Senstivity | NA |
Specificity | NA |
AUC | 0.904 |
Accuracy | NA |
Level Of Significance | p=0.00822 |
Method Used | RNASeqV2 and Illumina HiSeq 2000 miRNA sequencing |
Clinical | No |
Remarks | risk score = (0.420 × expression value of HOXB5 + 0.794 × expression value of GPC2 + 0.947 ×PGA5+0.473×AMBN). The 4-mRNA expression-based survival risk score was used to assign patients into a low-risk or high-risk group using a median risk score of 0.9558 as the cut- off. |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |